Steven Leili

Steven Leili has a work experience spanning several companies and roles. Steven is currently working at Entrada Therapeutics as the Executive Director, a position they have held since January 2023. Prior to this, they were the Sr. Director of Toxicology and Product Development at Entrada Therapeutics starting from June 2021.

Before joining Entrada Therapeutics, Steven worked at Abbvie (formerly Allergan) as the Executive Director from May 2020 to April 2021. In this role, they were responsible for drug development and advancing drug candidates from discovery through life-cycle management. Steven also oversaw and developed PhD toxicologists.

Prior to their time at Abbvie, Steven had a long tenure at Forest Laboratories (now Allergan) where they served as a Research Fellow, Director, and later as an Executive Director. Steven worked at Forest Laboratories from December 2007 to May 2020.

Steven's career began at Bristol Myers Squibb where they held the position of Study Director and Project Non-clinical Representative from December 1987 to December 2007.

Overall, Steven Leili has a strong background in drug development, toxicology, and project management, with experience across various multifunctional groups and a proven track record in advancing drug candidates.

Steven Leili's education history includes a Bachelor of Science (BS) degree in Biology from Montclair State University, a Doctor of Philosophy (PhD) degree in Animal Sciences from Rutgers University, and a Master's degree in Toxicology from St. John's University.